Point Therapeutics Announces Time Change for January 31, 2006 Webcast; Webcast on Phase 3 NSCLC Program and Clinical Update Move

Point Therapeutics, Inc. (NASDAQ:POTP) announced today
that it has changed the start time for its live webcast on Tuesday,
January 31 to 8:30 AM EST.
   The webcast may be accessed by visiting www.pther.com.

   About Point Therapeutics, Inc.:

   Point is developing a family of dipeptidyl peptidase (DPP)
inhibitors for use in cancer, type 2 diabetes and as vaccine
adjuvants. The Company is currently studying its lead product
candidate, talabostat, in a Phase 3 trial in metastatic NSCLC.
Additionally, talabostat is being evaluated in several Phase 2 trials;
including, as a single-agent in metastatic melanoma, in combination
with cisplatin in metastatic melanoma, in combination with rituximab
in advanced chronic lymphocytic leukemia, and in combination with
gemcitabine in metastatic pancreatic cancer. Point's portfolio also
includes two other DPP inhibitors in preclinical development--PT-630
for type 2 diabetes, and PT-510 as a vaccine adjuvant.

   Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements with respect to the company's clinical development
programs, the timing of initiation and completion of its clinical
trials, and the potential of talabostat to become an important
treatment for chronic lymphocytic leukemia cancer. Forward-looking
statements are statements that are not historical facts, and can be
identified by, among other things, the use of forward-looking
language, such as "believes," "feels," "expects," "may," "will,"
"should," "seeks," "plans," "schedule to," "anticipates" or "intends"
or the negative of those terms, or other variations of those terms of
comparable language, or by discussions of strategy or intentions. A
number of important factors could cause actual results to differ
materially from those projected or suggested in the forward looking
statement, including the risk factors described in Point's quarterly
report on Form 10-Q for the quarter ended September 30, 2005 and from
time to time in Point's periodic and other reports filed with the
Securities and Exchange Commission.